LaserBlood - Biophotonic Nanoparticle Blood Test

Non-invasive liquid biopsy test for early-stage prostate cancer detection using glycan analysis in blood serum. Achieves up to 90% accuracy using magnetic particle-based technology with minimal blood sample requirement of 10 microliters.

Advanced early detection test for lung cancer screening utilizing molecular diagnostic technology. This in-development product represents the company's expansion into early detection for pulmonary malignancies. The test is designed for high-risk population screening and clinical intervention.

Portable biosensor system for rapid, simultaneous detection of up to six blood analytes using nanotech sensors and AI algorithms. Processes whole blood samples directly on lab-on-chip cartridges, delivering results within minutes for clinical diagnostics including traumatic brain injury biomarker detection. Cloud-based data storage enables remote access and analysis.

A specialized molecular diagnostic test for early detection and risk assessment of pancreatic cancer using DNA methylation technology. Supports early diagnosis of this highly aggressive malignancy.

A DNA methylation-based molecular diagnostic test designed for early detection and risk assessment across multiple cancer types. The test utilizes proprietary methylation technology to identify cancer signals in biological samples.

Comprehensive in vitro diagnostic test system for hepatocellular carcinoma risk assessment in patients with chronic liver disease. Integrates AFP-L3 and DCP biomarker testing for improved early detection.

A molecular diagnostic test utilizing DNA methylation technology for early detection of lung cancer. Enables risk assessment and early diagnosis of lung malignancies through liquid biopsy methodology.

Liquid biopsy assay for real-time monitoring of circulating tumor markers and cells during perioperative periods to assess surgical outcomes and recurrence risk.

Diagnostic test for detection of cancer biomarkers in blood and body secretions. Identifies biomolecules produced and released by cancer cells for screening and monitoring purposes.

In-vitro diagnostic test for detecting tumor markers and cancer-related antigens in blood and other biological samples. The test aids in cancer screening, diagnosis, and treatment monitoring.

A portable diagnostic test kit for detecting occult blood, designed for early cancer screening in digestive tract-related conditions. The product received Class II medical device registration certification from Shandong Province Drug Supervision and Management Bureau. It is manufactured by Lixin Nuo Kang, a wholly-owned subsidiary of Linaxin Biotechnology, and represents the company's technological capabilities in in vitro diagnostics for home-based early cancer screening.

Laser-based diagnostic platform designed for rapid, multiplexed lateral flow testing with significantly reduced manufacturing costs. The technology provides sensitive and scalable point-of-care diagnostic capabilities for various clinical applications.